doi: 10.1016/j.femsim.2004.05.011.
Characterization of the human immune response to the UK anthrax vaccine
Affiliations
- PMID: 15364114
- DOI: 10.1016/j.femsim.2004.05.011
Item in Clipboard
Characterization of the human immune response to the UK anthrax vaccine
FEMS Immunol Med Microbiol.
.
Free article
Abstract
The anthrax bipartite lethal toxin (protective antigen (PA) and lethal factor (LF))-specific antibody responses of humans receiving the UK licensed anthrax vaccine were determined. The PA-specific IgG response peaked two weeks post immunization and fell back to pre-boost levels by week 12. The heterogeneity of the host population modulated the extent of the PA-specific antibody response. Significantly lower levels of LF-specific antibodies were also detected. Vaccinated individuals recognized the same PA epitope as the protective mouse lethal toxin neutralizing monoclonal 2D3 suggesting that this may also be a target for human protection.
Similar articles
-
Generation of a novel chimeric PALFn antigen of Bacillus anthracis and its immunological characterization in mouse model.Appl Microbiol Biotechnol. 2016 Oct;100(19):8439-51. doi: 10.1007/s00253-016-7684-4. Epub 2016 Jun 30. Appl Microbiol Biotechnol. 2016. PMID: 27364624
-
A plant based protective antigen [PA(dIV)] vaccine expressed in chloroplasts demonstrates protective immunity in mice against anthrax.Vaccine. 2011 Jun 15;29(27):4521-33. doi: 10.1016/j.vaccine.2011.03.082. Epub 2011 Apr 17. Vaccine. 2011. PMID: 21504775
-
A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores.Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13601-6. doi: 10.1073/pnas.0405557101. Epub 2004 Sep 1. Proc Natl Acad Sci U S A. 2004. PMID: 15342913 Free PMC article.
-
Neutralizing antibody and functional mapping of Bacillus anthracis protective antigen-The first step toward a rationally designed anthrax vaccine.Vaccine. 2016 Jan 2;34(1):13-9. doi: 10.1016/j.vaccine.2015.11.025. Epub 2015 Nov 21. Vaccine. 2016. PMID: 26611201 Review.
-
Progress and novel strategies in vaccine development and treatment of anthrax.Immunol Rev. 2011 Jan;239(1):221-36. doi: 10.1111/j.1600-065X.2010.00969.x. Immunol Rev. 2011. PMID: 21198675 Review.
Cited by
-
The early humoral immune response to Bacillus anthracis toxins in patients infected with cutaneous anthrax.FEMS Immunol Med Microbiol. 2011 Jul;62(2):164-72. doi: 10.1111/j.1574-695X.2011.00800.x. Epub 2011 Apr 15. FEMS Immunol Med Microbiol. 2011. PMID: 21401726 Free PMC article.
-
The anthrax vaccine adsorbed vaccine generates protective antigen (PA)-Specific CD4+ T cells with a phenotype distinct from that of naive PA T cells.Infect Immun. 2008 Oct;76(10):4538-45. doi: 10.1128/IAI.00324-08. Epub 2008 Aug 4. Infect Immun. 2008. PMID: 18678674 Free PMC article.
-
Analysis of epitope information related to Bacillus anthracis and Clostridium botulinum.Expert Rev Vaccines. 2008 Feb;7(1):55-74. doi: 10.1586/14760584.7.1.55. Expert Rev Vaccines. 2008. PMID: 18251694 Free PMC article. Review.
-
Combinations of monoclonal antibodies to anthrax toxin manifest new properties in neutralization assays.Infect Immun. 2013 Jun;81(6):1880-8. doi: 10.1128/IAI.01328-12. Epub 2013 Mar 18. Infect Immun. 2013. PMID: 23509144 Free PMC article.
-
Anthrax Vaccines in the 21st Century.Vaccines (Basel). 2024 Feb 3;12(2):159. doi: 10.3390/vaccines12020159. Vaccines (Basel). 2024. PMID: 38400142 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
